SomaLogic News and Events

Modified DNA aptamer inhibits IL-1α signaling

In an article published online in Nature Communications, scientists from SomaLogic and Yale University report that they have successfully generated a novel Slow Off-rate Modified Aptamer (SOMAmer) molecule that binds tightly to interleukin 1 alpha (IL-1α), an essential inflammatory protein implicated in cancer and other diseases.

read more

Protein changes may signal side effects in drug trials

In an article published “early online” in the American Heart Association journal Circulation, researchers at Pfizer, the Karolinska Institute, the University of California, San Francisco and SomaLogic describe how the measurement of blood-based protein changes in response to treatment with an experimental drug candidate may improve the efficiency and safety of clinical drug development.

read more

Reynolds appointed CEO of SomaLogic

SomaLogic announced today that Board of Directors member Alister W. (Al) Reynolds has agreed to become the next company Chief Executive Officer.  He is replacing Byron Hewett, who elected to step down from the role following several years of successfully leading the company through its initial growth into a successful commercial entity.

read more

For older news and press releases, please visit our archive.

For media-related matters